 |
市場調查報告書
商品編碼
1342922
全球運甲狀腺素蛋白澱粉樣變性治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測Global Transthyretin Amyloidosis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030 |
||||||
全球轉甲狀腺素蛋白澱粉樣變性治療市場的需求預計將從 2022 年的 69.4 億美元達到 2030 年近 147.3 億美元的市場規模，2023-2030 年研究期間年複合成長率為 8.72%。
運甲狀腺素蛋白澱粉樣變性治療可減少澱粉樣變性並限制澱粉樣蛋白的產生。運甲狀腺素蛋白澱粉樣變性是一種罕見且危及生命的疾病。這種疾病會影響一個人的多個器官，症狀包括食慾不振、腹瀉、椎管狹窄、便秘等。甲狀腺素運載蛋白澱粉樣變性的發生有多種原因，例如遺傳因素、骨髓疾病，甚至是其他一些潛在疾病。
市場動態：
支持性報銷計劃的存在和不斷成長的非裔美國人人口推動了轉甲狀腺素蛋白澱粉樣變性治療市場的發展。此外，疾病患病率的增加和對治療選擇的需求的增加預計將很快推動市場的成長。此外，新療法的推出預計將促進轉甲狀腺素蛋白澱粉樣變性治療市場的成長。此外，推動全球轉甲狀腺素蛋白澱粉樣變性治療市場的主要因素是認知的提高、診斷程序的進步、醫療保健服務的改善、發展中國家經濟的快速成長以及研發活動的增加。然而，轉甲狀腺素蛋白澱粉樣變性治療的認知度低和成本高可能會阻礙市場成長。
該研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球轉甲狀腺素蛋白澱粉樣變性治療市場的各個細分市場進行了包容性評估。轉甲狀腺素蛋白澱粉樣變性治療行業的成長和趨勢為本研究提供了整體方法。
區域分析：
本節介紹區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲對轉甲狀腺素蛋白澱粉樣變性治療市場的當前和未來需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。
該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。轉甲狀腺素蛋白澱粉樣變性治療市場的主要參與者包括輝瑞公司、強生服務公司、Ionis Pharmaceuticals Inc.、Alnylam Pharmaceuticals Inc.、BridgeBio Pharma Inc.、百時美施貴寶公司、Acrotech Biopharma、阿斯利康、Prothena 、SOM生物技術。本節包含競爭格局的整體視圖，包括各種戰略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。
如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。
目錄
第一章：前言
- 報告說明
- 客觀的
- 目標受眾
- 獨特的銷售主張 (USP) 和產品
- 研究範圍
- 研究方法論
- 市場研究過程
- 市場研究方法論
第 2 章：執行摘要
- 市場亮點
- 全球市場概況
第 3 章：轉甲狀腺素蛋白澱粉樣變性治療 - 行業分析
- 簡介 - 市場動態
- 市場促進因素
- 市場限制
- 機會
- 行業動態
- 波特五力分析
- 市場吸引力分析
- 按類型分類的市場吸引力分析
- 按治療方法進行的市場吸引力分析
- 按疾病類型分類的市場吸引力分析
- 按配銷通路分類的市場吸引力分析
- 市場吸引力分析：按地區
第 4 章：價值鏈分析
- 價值鏈分析
- 原料分析
- 原料清單
- 原料廠商清單
- 主要原料價格走勢
- 潛在買家名單
- 行銷管道
- 直效行銷
- 間接行銷
- 行銷管道發展趨勢
第 5 章：COVID-19 爆發的影響分析
第 6 章：全球轉甲狀腺素蛋白澱粉樣變性治療市場分析：按類型
- 按類型概述
- 歷史和預測數據
- 按類型分析
- ATTR-PN
- ATTR-CM
第 7 章：全球轉甲狀腺素蛋白澱粉樣變性治療市場分析：按治療方法
- 治療概述
- 歷史和預測數據
- 治療分析
- 標靶治療（Onpattro、Inotersen、Vyndaqel/Vyndamax）
- 支持療法
- 管道療法
第 8 章：全球轉甲狀腺素蛋白澱粉樣變性治療市場分析：按疾病類型
- 按疾病類型概述
- 歷史和預測數據
- 按疾病類型分析
- 遺傳性運甲狀腺素蛋白澱粉樣變性（多發性神經病、心肌病、混合型）
- 野生型澱粉樣變性
第 9 章：全球轉甲狀腺素蛋白澱粉樣變性治療市場分析：按配銷通路
- 按配銷通路分類的概覽
- 歷史和預測數據
- 按配銷通路分析
- 醫院藥房
- 專業藥房
- 零售藥店
- 網上藥店
第 10 章：全球轉甲狀腺素蛋白澱粉樣變性治療市場分析：按地理位置
- 區域展望
- 介紹
- 北美銷售分析
- 概述、歷史和預測銷售分析
- 北美按細分市場銷售分析
- 北美按國家/地區銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
- 歐洲銷售分析
- 概述、歷史和預測銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家/地區銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
- 亞太地區銷售分析
- 概述、歷史和預測銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 亞太地區其他地區銷售分析
- 拉丁美洲銷售分析
- 概述、歷史和預測銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家/地區銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
- 中東和非洲銷售分析
- 概述、歷史和預測銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析
第 11 章：轉甲狀腺素蛋白澱粉樣變性治療公司的競爭格局
- 運甲狀腺素蛋白澱粉樣變性治療市場競爭
- 夥伴關係/協作/協議
- 併購
- 新產品發布
- 其他發展
第 12 章：公司簡介
- 頂級公司股票分析
- 市場集中度
- Pfizer Inc.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Johnson & Johnson Services Inc.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Ionis Pharmaceuticals Inc.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Alnylam Pharmaceuticals Inc.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- BridgeBio Pharma Inc.
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Bristol-Myers Squibb Company
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Acrotech Biopharma
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- AstraZeneca
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- Prothena
- 公司簡介
- 公司收入
- 產品
- 最近的發展
- SOM Biotech
- 公司簡介
- 公司收入
- 產品
- 最近的發展
注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私營公司，則可能不包括在內
The global demand for Transthyretin Amyloidosis Treatment Market is presumed to reach the market size of nearly USD 14.73 BN by 2030 from USD 6.94 BN in 2022 with a CAGR of 8.72% under the study period 2023 - 2030.
Transthyretin amyloidosis treatment reduces amyloidosis and limits amyloid protein production. Transthyretin amyloidosis is a rare and life-threatening disease. This disease can affect multiple organs of a person with symptoms including loss of appetite, diarrhea, spinal stenosis, constipation, and many more. Transthyretin amyloidosis happens due to various causes like hereditary factors, bone marrow disorder, or even due to some other underlying sickness.
MARKET DYNAMICS:
The presence of supportive reimbursement programs and the growing African-American population drive the transthyretin amyloidosis treatment market. Moreover, the increasing prevalence of disease and rising need for treatment options are anticipated to drive the market's growth soon. Also, the introduction of novel therapies is expected to boost the growth of the transthyretin amyloidosis treatment market. Furthermore, the major factors driving the global transthyretin amyloidosis treatment market are increased awareness, advancements in diagnostic procedures, improvement in healthcare services, rapid economic growth in developing countries, and increased research and development activity. However, low awareness and high cost of transthyretin amyloidosis treatment may hamper the market growth.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of transthyretin amyloidosis treatment. The growth and trends of transthyretin amyloidosis treatment industry provide a holistic approach to this study.
MARKET SEGMENTATION:
This section of the transthyretin amyloidosis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
- ATTR-PN
- ATTR-CM
By Therapy
- Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax)
- Supportive Therapy
- Pipeline Therapy
By Disease Type
- Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type)
- Wild Type Amyloidosis
By Distribution Channel
- Hospital Pharmacies
- Specialty Pharmacies
- Retail Pharmacies
- Online Pharmacies
REGIONAL ANALYSIS:
This section covers the regional outlook, which accentuates current and future demand for the Transthyretin Amyloidosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the transthyretin amyloidosis treatment market include Pfizer Inc., Johnson & Johnson Services Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., BridgeBio Pharma Inc., Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Prothena, SOM Biotech. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . TRANSTHYRETIN AMYLOIDOSIS TREATMENT - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Therapy
- 3.7.3 Market Attractiveness Analysis By Disease Type
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
6 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY TYPE
- 6.1 Overview by Type
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Type
- 6.4 ATTR-PN Historic and Forecast Sales by Regions
- 6.5 ATTR-CM Historic and Forecast Sales by Regions
7 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY THERAPY
- 7.1 Overview by Therapy
- 7.2 Historical and Forecast Data
- 7.3 Analysis by Therapy
- 7.4 Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax) Historic and Forecast Sales by Regions
- 7.5 Supportive Therapy Historic and Forecast Sales by Regions
- 7.6 Pipeline Therapy Historic and Forecast Sales by Regions
8 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DISEASE TYPE
- 8.1 Overview by Disease Type
- 8.2 Historical and Forecast Data
- 8.3 Analysis by Disease Type
- 8.4 Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type) Historic and Forecast Sales by Regions
- 8.5 Wild Type Amyloidosis Historic and Forecast Sales by Regions
9 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL
- 9.1 Overview by Distribution Channel
- 9.2 Historical and Forecast Data
- 9.3 Analysis by Distribution Channel
- 9.4 Hospital Pharmacies Historic and Forecast Sales by Regions
- 9.5 Specialty Pharmacies Historic and Forecast Sales by Regions
- 9.6 Retail Pharmacies Historic and Forecast Sales by Regions
- 9.7 Online Pharmacies Historic and Forecast Sales by Regions
10 . GLOBAL TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY
- 10.1. Regional Outlook
- 10.2. Introduction
- 10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
- 10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
- 10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. Rest Of Asia Pacific Sales Analysis
- 10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
- 10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis
11 . COMPETITIVE LANDSCAPE OF THE TRANSTHYRETIN AMYLOIDOSIS TREATMENT COMPANIES
- 11.1. Transthyretin Amyloidosis Treatment Market Competition
- 11.2. Partnership/Collaboration/Agreement
- 11.3. Merger And Acquisitions
- 11.4. New Product Launch
- 11.5. Other Developments
12 . COMPANY PROFILES OF TRANSTHYRETIN AMYLOIDOSIS TREATMENT INDUSTRY
- 12.1. Top Company Share Analysis
- 12.2. Market Concentration Rate
- 12.3. Pfizer Inc.
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
- 12.4. Johnson & Johnson Services Inc.
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
- 12.5. Ionis Pharmaceuticals Inc.
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
- 12.6. Alnylam Pharmaceuticals Inc.
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
- 12.7. BridgeBio Pharma Inc.
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
- 12.8. Bristol-Myers Squibb Company
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
- 12.9. Acrotech Biopharma
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
- 12.10. AstraZeneca
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments
- 12.11. Prothena
- 12.11.1. Company Overview
- 12.11.2. Company Revenue
- 12.11.3. Products
- 12.11.4. Recent Developments
- 12.12. SOM Biotech
- 12.12.1. Company Overview
- 12.12.2. Company Revenue
- 12.12.3. Products
- 12.12.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- Analysis by Type (USD MN)
- ATTR-PN Market Sales by Geography (USD MN)
- ATTR-CM Market Sales by Geography (USD MN)
- Analysis Market by Therapy (USD MN)
- Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax) Market Sales by Geography (USD MN)
- Supportive Therapy Market Sales by Geography (USD MN)
- Pipeline Therapy Market Sales by Geography (USD MN)
- Analysis by Disease Type (USD MN)
- Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type) Market Sales by Geography (USD MN)
- Wild Type Amyloidosis Market Sales by Geography (USD MN)
- Analysis by Distribution Channel (USD MN)
- Hospital Pharmacies Market Sales by Geography (USD MN)
- Specialty Pharmacies Market Sales by Geography (USD MN)
- Retail Pharmacies Market Sales by Geography (USD MN)
- Online Pharmacies Market Sales by Geography (USD MN)
- Global Transthyretin Amyloidosis Treatment Market Sales by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Transthyretin Amyloidosis Treatment Report
- Market Research Process
- Market Research Methodology
- Global Transthyretin Amyloidosis Treatment Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Type
- Market Attractiveness Analysis by Therapy
- Market Attractiveness Analysis by Disease Type
- Market Attractiveness Analysis by Distribution Channel
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Type (USD MN)
- ATTR-PN Market Sales by Geography (USD MN)
- ATTR-CM Market Sales by Geography (USD MN)
- Global Market Analysis by Therapy (USD MN)
- Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax) Market Sales by Geography (USD MN)
- Supportive Therapy Market Sales by Geography (USD MN)
- Pipeline Therapy Market Sales by Geography (USD MN)
- Global Market Analysis by Disease Type (USD MN)
- Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type) Market Sales by Geography (USD MN)
- Wild Type Amyloidosis Market Sales by Geography (USD MN)
- Global Market Analysis by Distribution Channel (USD MN)
- Hospital Pharmacies Market Sales by Geography (USD MN)
- Specialty Pharmacies Market Sales by Geography (USD MN)
- Retail Pharmacies Market Sales by Geography (USD MN)
- Online Pharmacies Market Sales by Geography (USD MN)
- Global Market by Revenue
- North America Market by Revenue
- Europe Market by Revenue
- Asia Pacific Market by Revenue
- Latin America Market by Revenue
- Middle East & Africa Market by Revenue
- Recent Development in Industry
- Top Company Share Analysis
